Total fundingto date under this contract is $9

Total fundingto date under this contract is $9.4 million.Comtech Systems will provide services to support continued fielding of the U.S.Army's AN/TRC-170 terminals. These services will include the inspection andrepair of the terminals, and installation of the recently purchased AN/TRC-170modem upgrade kits. Comtech will also provide formal classroom and practicalhands-on training for personnel operating the upgraded AN/TRC-170 terminals.Comtech engineers will support Army field tests and network exercises, andengineering services on Department of Defense troposcatter systems other thanAN/TRC-170.Fred Kornberg, President and Chief Executive Officer of ComtechTelecommunications Corp., said, "We are extremely pleased by the additionalfunding, which further demonstrates Comtech's expertise and knowledge introposcatter communications systems and the U.S. Army's satisfaction with ourservices and support provided under this contract. We look forward to continuingour efforts on this important program."Comtech Systems, Inc.

() specializes in system design,integration, supply and commissioning of turnkey communication systems includingover-the-horizon microwave, line-of-sight microwave and satellite.Comtech Telecommunications Corp. designs, develops, produces and marketsinnovative products, systems and services for advanced communications solutions.The Company believes many of its solutions play a vital role in providing orenhancing communication capabilities when terrestrial communicationsinfrastructure is unavailable or ineffective. The Company conducts businessthrough three complementary segments: telecommunications transmission, mobiledata communications and RF microwave amplifiers. The Company sells products to adiverse customer base in the global commercial and government communicationsmarkets. The Company believes it is a market leader in the market segments thatit serves.Certain information in this press release contains statements that areforward-looking in nature and involve certain significant risks anduncertainties. Actual results could differ materially from such forward-lookinginformation.

The Company's Securities and Exchange Commission filings identifymany such risks and uncertainties. Any forward-looking information in this pressrelease is qualified in its entirety by the risks and uncertainties described insuch Securities and Exchange Commission filings.PCMTL-0-CONTACT: Comtech Telecommunications Corp. Media Contacts: Michael Porcelain, Senior Vice Presidentand Chief Financial Officer Jerome Kapelus, Senior Vice President,Strategy and Business Development 631-962-7000 . Integra LifeSciences Will Feature the CUSA EXcel+ Ultrasonic Tissue AblationSystem At the American Association of Neurological Surgeons Annual MeetingPLAINSBORO, N.J., April 30, 2009 (GLOBE NEWSWIRE) -- Integra LifeSciencesHoldings Corporation (Nasdaq:IART) will showcase its new CUSA EXcel(R)+ultrasonic tissue ablation system at the 2009 American Association ofNeurological Surgeons (AANS) meeting in San Diego, California, May 2-6, 2009. Itwill be featured at the Practical and Technical Aspects of TranssphenoidalSurgery course, preceding the meeting on May 2, and prominently displayed atIntegra's booth for hands-on demonstration throughout the meeting.The CUSA(R) systems are well recognized medical devices used in neurosurgicaland other surgical procedures for the controlled and selective removal of softtissues that are near critical structures. The CUSA(R) system may also be usedfor delicate bone sculpting procedures.

The CUSA EXcel(R)+ system is designed tomaintain clinical performance, while minimizing noise and maximizing durability."The CUSA EXcel(R)+ system has many standard features that provide an excellentlevel of precision and confidence. These include a simple user interface foreasy set up in the operating room, a powerful integrated aspiration system, andspecific functions to maximize system performance in laparoscopic applications,"said Christopher von Jako, Vice President of Marketing for IntegraNeuroSciences.The CUSA EXcel(R)+ system's features include TissueSelect(TM), which providessurgeons with advanced control of tissue fragmentation for tumor removal; andthe CUSA(R) Electrosurgery Module (CEM(TM)), which is unique to the CUSAEXcel(R) system and provides simultaneous electrosurgical and ultrasoniccapabilities with a press of a button. CEM(TM) provides more complete surgicalcontrol of hemostasis and reduces the amount of surgical equipment required fora procedure.The CUSA EXcel(R)+ system also includes the TipSelect(TM) feature, which enablescustomization of the handpiece for each procedure. It supports a 23 kHzmagnetostrictive handpiece that provides the power required to fragment toughfibrous and calcified tissues. The CUSA EXcel(R)+ system also includes the 36kHz handpiece, which, at more moderate power levels, is used for procedures thatrequire precision, tactile feedback and delicate control. A variety of specialtytips have also been developed for each handpiece for applications such as tumorremoval, liver resection and bone sculpting applications.Over 2,000 centers worldwide rely on CUSA(R) ultrasonic surgical ablationtechnology for a variety of procedures, including the removal of brain andabdominal tumors.

Integra currently offers a diverse line of CUSA(R) tissueablation products, including the CUSA NXT, CUSA EXcel(R)+ CUSA EXcel(R), CUSASelector(R), and CUSA(R) Dissectron(R) systems. The Integra NeuroSciences salesorganization sells the CUSA(R) systems. Integra NeuroSciences is a leadingprovider of implants, devices, instruments, and systems used in neurosurgery,neuromonitoring, neuro-trauma, and related neurocritical care. The IntegraNeuroSciences direct sales force is the largest neurosurgical sales force in theUnited States. Integra also has direct sales channels in Europe, Canada,Australia, and New Zealand. In all other markets, Integra NeuroSciences productsare sold through a network of distributors.Integra LifeSciences Holdings Corporation, a world leader in regenerativemedicine, is dedicated to improving the quality of life for patients through thedevelopment, manufacturing, and marketing of clinically relevant, innovative,and cost-effective surgical implants and medical instruments. Integra'sproducts, used primarily in neurosurgery, orthopedics and general surgery, areused to treat millions of patients every year.